Kinetic and thermodynamic characterization of HIV-1 protease inhibitors

被引:51
作者
Shuman, CF
Hämäläinen, MD
Danielson, UH
机构
[1] Uppsala Univ, Dept Biochem, SE-75123 Uppsala, Sweden
[2] Biacore AB, SE-75450 Uppsala, Sweden
关键词
HIV protease; kinetics; thermodynamics; interactions; biosensor;
D O I
10.1002/jmr.655
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Interaction kinetic and thermodynamic analyses provide information beyond that obtained in general inhibition studies, and may contribute to the design of improved inhibitors and increased understanding of molecular interactions. Thus, a biosensor-based method was used to characterize the interactions between HIV-1 protease and seven inhibitors, revealing distinguishing kinetic and thermodynamic characteristics for the inhibitors. Lopinavir had fast association and the highest affinity of the tested compounds, and the interaction kinetics were less temperature-dependent as compared with the other inhibitors. Amprenavir, indinavir and ritonavir showed non-linear temperature dependencies of the kinetics. The free energy, enthalpy and entropy (DeltaG, DeltaH, DeltaS) were determined, and the energetics of complex association (DeltaG(on), DeltaH(on), DeltaS(on)) and dissociation (DeltaG(off), DeltaH(off), DeltaS(off)) were resolved. In general, the energetics for the studied inhibitors was in the same range, with the negative free energy change (DeltaG < 0) due primarily to increased entropy (DeltaS > 0). Thus, the driving force of the interaction was increased degrees of freedom in the system (entropy) rather than the formation of bonds between the enzyme and inhibitor (enthalpy). Although the DeltaG(on) and DeltaGoff were in the same range for all inhibitors, the enthalpy and entropy terms contributed differently to association and dissociation, distinguishing these phases energetically. Dissociation was accompanied by positive enthalpy (DeltaH(off) > 0) and negative entropy (DeltaS(off) < 0) changes, whereas association for all inhibitors except lopinavir had positive entropy changes (DeltaS(on) > 0), demonstrating unique energetic characteristics for lopinavir. This study indicates that this type of data will be useful for the characterization of target-ligand interactions and the development of new inhibitors of HIV-1 protease. Copyright (C) 2004 John Wiley Sons, Ltd.
引用
收藏
页码:106 / 119
页数:14
相关论文
共 48 条
[11]   van't Hoff and calorimetric enthalpies from isothermal titration calorimetry: Are there significant discrepancies? [J].
Horn, JR ;
Russell, D ;
Lewis, EA ;
Murphy, KP .
BIOCHEMISTRY, 2001, 40 (06) :1774-1778
[12]   Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease [J].
Kaldor, SW ;
Kalish, VJ ;
Davies, JF ;
Shetty, BV ;
Fritz, JE ;
Appelt, K ;
Burgess, JA ;
Campanale, KM ;
Chirgadze, NY ;
Clawson, DK ;
Dressman, BA ;
Hatch, SD ;
Khalil, DA ;
Kosa, MB ;
Lubbehusen, PP ;
Muesing, MA ;
Patick, AK ;
Reich, SH ;
Su, KS ;
Tatlock, JH .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (24) :3979-3985
[13]  
Karlsson R, 1999, J MOL RECOGNIT, V12, P285, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<285::AID-JMR469>3.0.CO
[14]  
2-Y
[15]   Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors [J].
Karlsson, R ;
Falt, A .
JOURNAL OF IMMUNOLOGICAL METHODS, 1997, 200 (1-2) :121-133
[16]   Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy [J].
Kempf, DJ ;
Sham, HL ;
Marsh, KC ;
Flentge, CA ;
Betebenner, D ;
Green, BE ;
McDonald, E ;
Vasavanonda, S ;
Saldivar, A ;
Wideburg, NE ;
Kati, WM ;
Ruiz, L ;
Zhao, C ;
Fino, LM ;
Patterson, J ;
Molla, A ;
Plattner, JJ ;
Norbeck, DW .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (04) :602-617
[17]   CRYSTAL-STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH VX-478, A POTENT AND ORALLY BIOAVAILABLE INHIBITOR OF THE ENZYME [J].
KIM, EE ;
BAKER, CT ;
DWYER, MD ;
MURCKO, MA ;
RAO, BG ;
TUNG, RD ;
NAVIA, MA .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1995, 117 (03) :1181-1182
[18]   Resistance to HIV protease inhibitors: A comparison of enzyme inhibition and antiviral potency [J].
Klabe, RM ;
Bacheler, LT ;
Ala, PJ ;
Erickson-Viitanen, S ;
Meek, JL .
BIOCHEMISTRY, 1998, 37 (24) :8735-8742
[19]  
LEATHERBARROW RJ, 1998, GRAFIT VERSION 5 0
[20]   Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings [J].
Lipinski, CA ;
Lombardo, F ;
Dominy, BW ;
Feeney, PJ .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 23 (1-3) :3-25